Skip navigation
Merrion pharmaceuticals - making medicines better
HomeLink
Skip navigation

Executive Management

Merrion's executive management has extensive life science industry experience with expertise across all aspects of the product life cycle. The team has an established record of accomplishment in all facets of the pharmaceutical industry.

John Fox

John S. Fox, PhD, Chief Executive Officer
John joined Merrion in 2008 as Chief Development Officer. Prior to joining Merrion, John was Chief Operating Officer of Hunter Fleming, a company he co-founded in 1999 to develop early stage projects derived from University research and focussed on neuroprotection. Hunter Fleming was subsequently acquired by Newron Pharmaceuticals SpA. John has spent over 25 years in the pharmaceutical industry in a variety of pharmaceutical development and operational roles and has experience of both SME and multinational companies. Prior to setting up Hunter Fleming he was Head of the Clinical Research Coordination Group in the UK affiliate of Eli Lilly & Co. and later Director of Planning for Shire Pharmaceuticals. He has also held non-executive Board roles with the technology transfer company of the University of Southampton, Southampton Asset Management Ltd., and until recently as Chairman of Endocrine Pharmaceuticals Ltd. John holds a BSc and PhD in Biochemistry from Queens University Belfast and an MBA from Henley Management College.

Thomas Leonard

Thomas W. Leonard, PhD, Vice President & Chief Scientific Officer
Thomas has 27 years of new product formulation and drug development management experience. He joined Merrion from Endeavor Pharmaceuticals, Inc., where he served as Vice President and Chief Scientific Officer. Previously, he was Senior Director, Product Development at aaiPharma. Thomas also held the position of Associate Director at Wyeth-Ayerst Research. Thomas holds a BS in Pharmacy from The University of South Carolina and a PhD in Pharmaceutics from the Medical College of Virginia. He has published extensively in his field, holds numerous approved patents in the areas of drug development, and is an active member of several professional pharmaceutical organisations.


back to top